A new analysis has found that the long-term use of guselkumab (TREMFYA) for the treatment of psoriasis and/or psoriatic arthritis (PsA) is consistently safe, comparable to placebo outcomes seen in previous clinical trials. The results were presented at the Congress of Clinical Rheumatology (CCR) East 2023 Annual Meeting in Destin, FL. An interleukin-23 (IL-23) inhibitor, guselkumab has shown benefits and safety in patients with moderate to severe psoriasis and with active PsA. The integrated analysis included safety data from 11 trials and observed 10,787 patient-years of guselkumab follow-up. The team concluded that their analysis showed the biologic was favorably and consistently safe.
